Nanobiotix S.A. (NBTX) Stock

About Nanobiotix S.A.

Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.

Nanobiotix S.A. (NBTX) stock trades at $40.18 with a market capitalization of $2.03B. The stock is valued at a price-to-earnings (P/E) ratio of -68.71, price-to-book of -19.67, price-to-sales of 60.03. Over the past 52 weeks the stock has ranged between $6.09 and $57.14, and currently trades 29.7% below its 52-week high.

On profitability, Nanobiotix S.A. generates a return on equity (ROE) of 31.23% — well above the market average, a sign of a high-quality business, return on capital employed of -105.51%, an operating margin of -36.67%, a net profit margin of -80.83%.

Official website: www.nanobiotix.com